Chemotherapy Pharmacodynamics and Neuroimaging and Neurocognitive Outcomes in Long-Term Survivors of Childhood Acute Lymphoblastic Leukemia [Treatment-Related Complications]
Conclusion
Survivors of childhood acute lymphoblastic leukemia treated on contemporary chemotherapy-only protocols demonstrate executive dysfunction. A higher plasma concentration of methotrexate was associated with executive dysfunction as well as with a thicker cortex and higher activity in frontal brain regions, regions often associated with executive function. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 19, 2016 Category: Cancer & Oncology Authors: Krull, Cheung, Liu, Fellah, Reddick, Brinkman, Kimberg, Ogg, Srivastava, Pui, Robison, Hudson Tags: Chemotherapy, Acute Lymphoblastic Leukemia, Long Term Survival & Late Effects, Outcomes Research Treatment-Related Complications Source Type: research
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer [Urologic Oncology]
Conclusion
In chemotherapy-naïve men with mCRPC, tasquinimod significantly improved rPFS compared with placebo. However, no OS benefit was observed. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 19, 2016 Category: Cancer & Oncology Authors: Sternberg, Armstrong, Pili, Ng, Huddart, Agarwal, Khvorostenko, Lyulko, Brize, Vogelzang, Delva, Harza, Thanos, James, Werbrouck, Bogemann, Hutson, Milecki, Chowdhury, Gallardo, Schwartsmann, Pouget, Baton, Nederman, Tuvesson, Carducci Tags: Systemic Therapy Urologic Oncology Source Type: research
Comparative Effectiveness of Treatment Strategies for Bladder Cancer With Clinical Evidence of Regional Lymph Node Involvement [Urologic Oncology]
Conclusion
A subset of patients with cN+ bladder cancer achieves long-term survival. Combined-modality therapy, with chemotherapy and cystectomy, is associated with the best outcomes. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 19, 2016 Category: Cancer & Oncology Authors: Galsky, Stensland, Sfakianos, Mehrazin, Diefenbach, Mohamed, Tsao, Boffetta, Wiklund, Oh, Mazumdar, Ferket Tags: Surgery, Chemotherapy, Combined Modality Therapy Urologic Oncology Source Type: research
Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma [Melanoma]
Conclusion
T-VEC with ipilimumab had a tolerable safety profile, and the combination appeared to have greater efficacy than either T-VEC or ipilimumab monotherapy. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 19, 2016 Category: Cancer & Oncology Authors: Puzanov, Milhem, Minor, Hamid, Li, Chen, Chastain, Gorski, Anderson, Chou, Kaufman, Andtbacka Tags: Combined Modality Melanoma Source Type: research
Health Care Segregation, Physician Recommendation, and Racial Disparities in BRCA1/2 Testing Among Women With Breast Cancer [Breast Cancer]
Conclusion
Although black and white patients with breast cancer tend to see different surgeons and oncologists, this distribution does not contribute to disparities in BRCA1/2 testing. Instead, residual racial differences in testing after accounting for patient and physician characteristics are largely attributable to differences in physician recommendations. Efforts to address these disparities should focus on ensuring equity in testing recommendations. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 19, 2016 Category: Cancer & Oncology Authors: McCarthy, Bristol, Domchek, Groeneveld, Kim, Motanya, Shea, Armstrong Tags: Diagnosis & Staging Breast Cancer Source Type: research
Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance) [Breast Cancer]
Conclusion
The addition of bevacizumab to letrozole improved PFS in hormone receptor–positive MBC, but this benefit was associated with a markedly increased risk of grade 3 to 4 toxicities. Research on predictive markers will be required to clarify the role of bevacizumab in this setting. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 19, 2016 Category: Cancer & Oncology Authors: Dickler, Barry, Cirrincione, Ellis, Moynahan, Innocenti, Hurria, Rugo, Lake, Hahn, Schneider, Tripathy, Carey, Winer, Hudis Tags: Hormonal Therapy Breast Cancer Source Type: research
Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group [Pediatric Oncology]
Conclusion
Chemotherapy was substantially reduced safely in one-quarter of children with ALL who were selected on the basis of undetectable MRD levels, without jeopardizing the survival rate. Outcomes of patients with intermediate and high levels of MRD improved with therapy intensification. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 19, 2016 Category: Cancer & Oncology Authors: Pieters, de Groot-Kruseman, Van der Velden, Fiocco, van den Berg, de Bont, Egeler, Hoogerbrugge, Kaspers, Van der Schoot, De Haas, Van Dongen Tags: Acute Lymphoblastic Leukemia Pediatric Oncology Source Type: research
Biomarker Panel for Chronic Graft-Versus-Host Disease [Hematologic Malignancy]
Conclusion
We conclude that the biomarker panel measured at diagnosis or day +100 after HCT may allow patient stratification according to risk of cGVHD. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 19, 2016 Category: Cancer & Oncology Authors: Yu, Storer, Kushekhar, Abu Zaid, Zhang, Gafken, Ogata, Martin, Flowers, Hansen, Arora, Cutler, Jagasia, Pidala, Hamilton, Chen, Pusic, Lee, Paczesny Tags: Leukemia Hematologic Malignancy Source Type: research
Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial [Hematologic Malignancy]
Conclusion
HT in patients with FL who previously responded to immunochemotherapy is an early event associated with a poor outcome that may deserve intensive salvage with autologous stem cell transplantation. These data emphasize the necessity for biopsy at the first recurrence of FL. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 19, 2016 Category: Cancer & Oncology Authors: Sarkozy, Trneny, Xerri, Wickham, Feugier, Leppa, Brice, Soubeyran, Gomes Da Silva, Mounier, Offner, Dupuis, Caballero, Canioni, Paula, Delarue, Zachee, Seymour, Salles, Tilly Tags: Risk factors, Epidemiology, Diagnosis & Staging, Chemotherapy Hematologic Malignancy Source Type: research
No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial [Rapid Communication]
Conclusion
To the best of our knowledge, this is the first long-term analysis confirming that GnRHa is not efficient in preventing chemotherapy-induced POF in young patients with lymphoma and did not influence future pregnancy rate. These results reopen the debate about the drug’s benefit in that it should not be recommended as standard for fertility preservation in patients with lymphoma. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 19, 2016 Category: Cancer & Oncology Authors: Demeestere, Brice, Peccatori, Kentos, Dupuis, Zachee, Casasnovas, Van Den Neste, Dechene, De Maertelaer, Bron, Englert Tags: Quality of Life, Menopausal Symptoms, Rapid Communications Source Type: research
Will a Better Understanding of the Problem With Transformed Follicular Lymphoma Lead to Better Outcomes? [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 19, 2016 Category: Cancer & Oncology Authors: Link Tags: Diagnosis & Staging EDITORIALS Source Type: research
Appraising the Biological Evidence for and Against the Utility of GnRHa for Preservation of Fertility in Patients With Cancer [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 19, 2016 Category: Cancer & Oncology Authors: Oktay, Bedoschi Tags: Quality of Care EDITORIALS Source Type: research
Advertising [ONCOLOGY CAREER CENTER]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 19, 2016 Category: Cancer & Oncology Tags: ONCOLOGY CAREER CENTER Source Type: research
Erratum [erratum]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Tags: ERRATUM Source Type: research
Reply to H. Laubli et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Authors: Macbeth, Noble Tags: CORRESPONDENCE Source Type: research
